Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8+ T Cell Response.

Khong H, Volmari A, Sharma M, Dai Z, Imo CS, Hailemichael Y, Singh M, Moore DT, Xiao Z, Huang XF, Horvath TD, Hawke DH, Overwijk WW.

J Immunol. 2018 May 15;200(10):3464-3474. doi: 10.4049/jimmunol.1700467. Epub 2018 Apr 11.

PMID:
29643190
2.

Neutrophil-to-lymphocyte Ratio (NLR) as a predictor for recurrence in patients with stage III melanoma.

Ma J, Kuzman J, Ray A, Lawson BO, Khong B, Xuan S, Hahn AW, Khong HT.

Sci Rep. 2018 Mar 6;8(1):4044. doi: 10.1038/s41598-018-22425-3.

3.

Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.

Hailemichael Y, Woods A, Fu T, He Q, Nielsen MC, Hasan F, Roszik J, Xiao Z, Vianden C, Khong H, Singh M, Sharma M, Faak F, Moore D, Dai Z, Anthony SM, Schluns KS, Sharma P, Engelhard VH, Overwijk WW.

J Clin Invest. 2018 Apr 2;128(4):1338-1354. doi: 10.1172/JCI93303. Epub 2018 Feb 26.

4.

Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain.

Singh M, Vianden C, Cantwell MJ, Dai Z, Xiao Z, Sharma M, Khong H, Jaiswal AR, Faak F, Hailemichael Y, Janssen LME, Bharadwaj U, Curran MA, Diab A, Bassett RL, Tweardy DJ, Hwu P, Overwijk WW.

Nat Commun. 2017 Nov 13;8(1):1447. doi: 10.1038/s41467-017-01572-7.

5.

A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors.

Cohen AL, Ray A, Van Brocklin M, Burnett DM, Bowen RC, Dyess DL, Butler TW, Dumlao T, Khong HT.

Oncotarget. 2016 Dec 26;8(32):52413-52419. doi: 10.18632/oncotarget.14183. eCollection 2017 Aug 8.

6.

HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes.

Mbofung RM, McKenzie JA, Malu S, Zhang M, Peng W, Liu C, Kuiatse I, Tieu T, Williams L, Devi S, Ashkin E, Xu C, Huang L, Zhang M, Talukder AH, Tripathi SC, Khong H, Satani N, Muller FL, Roszik J, Heffernan T, Allison JP, Lizee G, Hanash SM, Proia D, Amaria R, Davis RE, Hwu P.

Nat Commun. 2017 Sep 6;8(1):451. doi: 10.1038/s41467-017-00449-z.

7.

Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis.

Gardner LJ, Ward M, Andtbacka RHI, Boucher KM, Bowen GM, Bowles TL, Cohen AL, Grossmann K, Hitchcock YJ, Holmen SL, Hyngstrom J, Khong H, McMahon M, Monroe MM, Ross CB, Suneja G, Wada D, Grossman D.

Melanoma Res. 2017 Oct;27(5):477-484. doi: 10.1097/CMR.0000000000000382.

PMID:
28800031
8.

A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast Cancer.

Werner TL, Ray A, Lamb JG, VanBrocklin M, Hueftle K, Cohen AL, Beck AC, Buys SS, Dyess DL, Butler TW, Dumlao TL, Neumayer L, Khong HT.

Clin Breast Cancer. 2017 Nov;17(7):503-509. doi: 10.1016/j.clbc.2017.04.010. Epub 2017 Apr 29.

PMID:
28579139
9.

Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis.

Bowen RC, Little NAB, Harmer JR, Ma J, Mirabelli LG, Roller KD, Breivik AM, Signor E, Miller AB, Khong HT.

Oncotarget. 2017 May 9;8(19):32171-32189. doi: 10.18632/oncotarget.16291. Review.

10.
11.

CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner.

Huang L, Wang Z, Liu C, Xu C, Mbofung RM, McKenzie JA, Khong H, Hwu P, Peng W.

Oncogene. 2017 Jul 13;36(28):4081-4086. doi: 10.1038/onc.2017.35. Epub 2017 Mar 6.

12.

Complete response to azacitidine priming and nab-paclitaxel in non-Hodgkin lymphoma resistant to biochemotherapy.

Bowen RC, Hahn AW, Butler TW, Khong HT.

Mol Clin Oncol. 2017 Jan;6(1):122-124. doi: 10.3892/mco.2016.1090. Epub 2016 Nov 23.

13.

A Case Report of Pneumocystis Jiroveci Pneumonia in a Patient with Metastatic Breast Cancer.

Ray A, Khong B, Khong HT.

Anticancer Res. 2016 Dec;36(12):6673-6676.

PMID:
27920001
14.

Adjuvants for peptide-based cancer vaccines.

Khong H, Overwijk WW.

J Immunother Cancer. 2016 Sep 20;4:56. doi: 10.1186/s40425-016-0160-y. eCollection 2016. Review.

15.

miR-125b regulates differentiation and metabolic reprogramming of T cell acute lymphoblastic leukemia by directly targeting A20.

Liu Z, Smith KR, Khong HT, Huang J, Ahn EE, Zhou M, Tan M.

Oncotarget. 2016 Nov 29;7(48):78667-78679. doi: 10.18632/oncotarget.12018.

16.

A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma.

Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RH, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong HT.

Oncotarget. 2016 Sep 27;7(39):64390-64399. doi: 10.18632/oncotarget.10453.

17.

Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.

Singh M, Khong H, Dai Z, Huang XF, Wargo JA, Cooper ZA, Vasilakos JP, Hwu P, Overwijk WW.

J Immunol. 2014 Nov 1;193(9):4722-31. doi: 10.4049/jimmunol.1401160. Epub 2014 Sep 24.

18.

Adequacy of 5-mm surgical excision margins for non-lentiginous melanoma in situ.

Duffy KL, Truong A, Bowen GM, Andtbacka RH, Hyngstrom J, Bowles T, Grossmann K, Khong H, Hyde M, Florell SR, Bowen AR, Wada D, Grossman D.

J Am Acad Dermatol. 2014 Oct;71(4):835-8. doi: 10.1016/j.jaad.2014.06.044. No abstract available.

19.

Cost-utility of metal-on-metal hip resurfacing compared to conventional total hip replacement in young active patients with osteoarthritis.

Heintzbergen S, Kulin NA, Ijzerman MJ, Steuten LM, Werle J, Khong H, Marshall DA.

Value Health. 2013 Sep-Oct;16(6):942-52. doi: 10.1016/j.jval.2013.06.021.

20.

Closing the personalized medicine information gap: HER2 test documentation practice.

Ferrusi IL, Earle CC, Trudeau M, Leighl NB, Pullenayegum E, Khong H, Hoch JS, Marshall DA.

Am J Manag Care. 2013 Jan;19(1):838-44.

21.

miR-125b functions as a key mediator for snail-induced stem cell propagation and chemoresistance.

Liu Z, Liu H, Desai S, Schmitt DC, Zhou M, Khong HT, Klos KS, McClellan S, Fodstad O, Tan M.

J Biol Chem. 2013 Feb 8;288(6):4334-45. doi: 10.1074/jbc.M112.419168. Epub 2012 Dec 19.

22.

Sentinel lymph node biopsy for melanoma in pregnant women.

Andtbacka RH, Donaldson MR, Bowles TL, Bowen GM, Grossmann K, Khong H, Grossman D, Anker C, Florell SR, Bowen A, Duffy KL, Leachman SA, Noyes RD.

Ann Surg Oncol. 2013 Feb;20(2):689-96. doi: 10.1245/s10434-012-2633-7. Epub 2012 Oct 6.

PMID:
23054111
23.

Malaysianol B, an oligostilbenoid derivative from Dryobalanops lanceolata.

Wibowo A, Ahmat N, Hamzah AS, Low AL, Mohamad SA, Khong HY, Sufian AS, Manshoor N, Takayama H.

Fitoterapia. 2012 Dec;83(8):1569-75. doi: 10.1016/j.fitote.2012.09.004. Epub 2012 Sep 13.

PMID:
22982329
24.

TGFβ1 overexpression by keratinocytes alters skin dendritic cell homeostasis and enhances contact hypersensitivity.

Mohammed J, Gunderson AJ, Khong HH, Koubek RD, Udey MC, Glick AB.

J Invest Dermatol. 2013 Jan;133(1):135-43. doi: 10.1038/jid.2012.241. Epub 2012 Jul 26.

25.

Comparative effectiveness of alternative clinical pathways for primary hip and knee joint replacement patients: a pragmatic randomized, controlled trial.

Gooch K, Marshall DA, Faris PD, Khong H, Wasylak T, Pearce T, Johnston DW, Arnett G, Hibbert J, Beaupre LA, Zernicke RF, Frank C.

Osteoarthritis Cartilage. 2012 Oct;20(10):1086-94. doi: 10.1016/j.joca.2012.06.017. Epub 2012 Jul 11.

26.

The pyranoxanthone inophyllin A induces oxidative stress mediated-apoptosis in Jurkat T lymphoblastic leukemia cells.

Chan KM, Hamzah R, Rahaman AA, Jong VY, Khong HY, Rajab NF, Ee GC, Inayat-Hussain SH.

Food Chem Toxicol. 2012 Aug;50(8):2916-22. doi: 10.1016/j.fct.2012.04.048. Epub 2012 May 18.

PMID:
22613213
27.

Functional outcomes for 2 years comparing hip resurfacing and total hip arthroplasty.

Alberta Hip Improvement Project, MacKenzie JR, O'Connor GJ, Marshall DA, Faris PD, Dort LC, Khong H, Parker RD, Werle JR, Beaupre LA, Frank CB.

J Arthroplasty. 2012 May;27(5):750-7.e2. doi: 10.1016/j.arth.2011.10.004. Epub 2012 Jan 28.

PMID:
22285258
28.

Measuring the value of total hip and knee arthroplasty: considering costs over the continuum of care.

Marshall DA, Wasylak T, Khong H, Parker RD, Faris PD, Frank C.

Clin Orthop Relat Res. 2012 Apr;470(4):1065-72. doi: 10.1007/s11999-011-2026-4.

29.

Comparison of risk factors between preterm and term infants hospitalized for severe respiratory syncytial virus in the Russian Federation.

Gooch KL, Notario GF, Schulz G, Gudkov KM, Buesch K, Khong H, Campbell A.

Int J Womens Health. 2011;3:133-8. doi: 10.2147/IJWH.S16608. Epub 2011 May 6.

30.

Demethylating Agents in the Treatment of Cancer.

Howell PM, Liu Z, Khong HT.

Pharmaceuticals (Basel). 2010 Jul 2;3(7):2022-2044. Review.

31.

Activated CD4+ T cells enhance radiation effect through the cooperation of interferon-gamma and TNF-alpha.

Wang Y, Radfar S, Khong HT.

BMC Cancer. 2010 Feb 23;10:60. doi: 10.1186/1471-2407-10-60.

32.
33.

Activated CD4+ T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo.

Radfar S, Wang Y, Khong HT.

J Immunol. 2009 Nov 15;183(10):6800-7. doi: 10.4049/jimmunol.0901747. Epub 2009 Oct 21.

34.

Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth.

Zhao YH, Zhou M, Liu H, Ding Y, Khong HT, Yu D, Fodstad O, Tan M.

Oncogene. 2009 Oct 22;28(42):3689-701. doi: 10.1038/onc.2009.229. Epub 2009 Aug 10.

PMID:
19668225
35.

The Alberta Hip and Knee Replacement Project: a model for health technology assessment based on comparative effectiveness of clinical pathways.

Gooch KL, Smith D, Wasylak T, Faris PD, Marshall DA, Khong H, Hibbert JE, Parker RD, Zernicke RF, Beaupre L, Pearce T, Johnston DW, Frank CB.

Int J Technol Assess Health Care. 2009 Apr;25(2):113-23. doi: 10.1017/S0266462309090163.

PMID:
19366494
36.

Prolactin receptor mRNA is upregulated in discus fish (Symphysodon aequifasciata) skin during parental phase.

Khong HK, Kuah MK, Jaya-Ram A, Shu-Chien AC.

Comp Biochem Physiol B Biochem Mol Biol. 2009 May;153(1):18-28. doi: 10.1016/j.cbpb.2009.01.005. Epub 2009 Jan 14.

PMID:
19272315
37.

Upregulated mRNA expression of desaturase and elongase, two enzymes involved in highly unsaturated fatty acids biosynthesis pathways during follicle maturation in zebrafish.

Ishak SD, Tan SH, Khong HK, Jaya-Ram A, Enyu YL, Kuah MK, Shu-Chien AC.

Reprod Biol Endocrinol. 2008 Nov 24;6:56. doi: 10.1186/1477-7827-6-56.

38.

Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.

Barve M, Bender J, Senzer N, Cunningham C, Greco FA, McCune D, Steis R, Khong H, Richards D, Stephenson J, Ganesa P, Nemunaitis J, Ishioka G, Pappen B, Nemunaitis M, Morse M, Mills B, Maples PB, Sherman J, Nemunaitis JJ.

J Clin Oncol. 2008 Sep 20;26(27):4418-25. doi: 10.1200/JCO.2008.16.6462.

PMID:
18802154
39.

Immunotherapy of melanoma: a critical review of current concepts and future strategies.

Riker AI, Radfar S, Liu S, Wang Y, Khong HT.

Expert Opin Biol Ther. 2007 Mar;7(3):345-58. Review.

PMID:
17309326
40.

Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes.

Zhao Y, Zheng Z, Khong HT, Rosenberg SA, Morgan RA.

J Immunother. 2006 Jul-Aug;29(4):398-406.

41.

Stress-induced response, localization, and regulation of the Pmk1 cell integrity pathway in Schizosaccharomyces pombe.

Madrid M, Soto T, Khong HK, Franco A, Vicente J, Pérez P, Gacto M, Cansado J.

J Biol Chem. 2006 Jan 27;281(4):2033-43. Epub 2005 Nov 16.

42.

Generating renal cancer-reactive T cells using dendritic cells (DCs) to present autologous tumor.

Wang QJ, Hanada K, Perry-Lalley D, Bettinotti MP, Karpova T, Khong HT, Yang JC.

J Immunother. 2005 Nov-Dec;28(6):551-9.

PMID:
16224272
43.

Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy.

Liu G, Akasaki Y, Khong HT, Wheeler CJ, Das A, Black KL, Yu JS.

Oncogene. 2005 Aug 4;24(33):5226-34.

PMID:
15897911
44.

Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression.

Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA, Robbins PF.

J Immunother. 2005 May-Jun;28(3):258-67.

45.

Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines.

Zhao Y, Zheng Z, Robbins PF, Khong HT, Rosenberg SA, Morgan RA.

J Immunol. 2005 Apr 1;174(7):4415-23.

46.

Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP.

Trends Immunol. 2005 Feb;26(2):111-7. Review. No abstract available. Erratum in: Trends Immunol. 2005 Jun;26(6):298.

47.

Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen.

Khong HT, Yang JC, Topalian SL, Sherry RM, Mavroukakis SA, White DE, Rosenberg SA.

J Immunother. 2004 Nov-Dec;27(6):472-7.

49.

Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma.

Liu G, Khong HT, Wheeler CJ, Yu JS, Black KL, Ying H.

J Immunother. 2003 Jul-Aug;26(4):301-12.

PMID:
12843792
50.

Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

Khong HT, Restifo NP.

Nat Immunol. 2002 Nov;3(11):999-1005. Review.

Supplemental Content

Support Center